EN DE
Watch TegoScience Inc for free: once a week we email you where price and fair value stand.
Data-driven stock valuation

TegoScience Inc (191420) fair value: what the stock is really worth

As of Nov 19, 2026: fair value (intrinsic value) of TegoScience Inc stock KRW 5,634, price KRW 6,440, that is 12.5% below the price, quality 34 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare KR · ISIN KR7191420009

TI TegoScience Inc logo Thin data Nov 16, 2026

TegoScience Inc

191420 · KQ

Expensive (fair value 13% below the price), weak company and falling price: meets none of the 3 rules.

Follow free in the weekly email
Solidly profitable · 16.0% net margin (TTM) 
Low debt 
Profit last quarter +111% vs. a year ago. 
Mixed vs. peers (4/10) 
Fair value 5,634 KRW · Overvalued 
Quality 34/100 
Falling price (downtrend) 
Weak Growth (revenue 5y −7.5 %/yr in KRW) 
Negative free cash flow 
Narrow moat 37/100
Thin data 
Estimate
Watch TegoScience Inc for free: once a week we email you where price and fair value stand. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

29,900 KRW 5,600 KRW Fair Value 5,634 KRW Jun 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.

How to read this chart

60‑month range 5,600 KRW – 29,900 KRW · fair‑value band 4,225 KRW – 7,042 KRW · the 6,440 KRW price screens above the 5,634 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.

Follow TegoScience in your weekly email

Every Wednesday you see whether TegoScience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

TegoScience Inc. produces and sells wound-healing skin cell therapy products from human epithelial cells in South Korea. The company's products include Holoderm, Kaloderm, and Rosmir. It also provides Neoderm, contract research, and Skinbank services.

Show moreShow less

The company was founded in 2001 and is based in Seoul, South Korea.

Stock analysis

TegoScience Inc (191420) currently trades at 6,440 KRW, while our estimate is 5,634 KRW, 13% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 4,225 KRW (bear) to 7,042 KRW (bull), the price of 6,440 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

TegoScience Inc reported revenue of 5.9B KRW in FY2025 versus 8.3B KRW in FY2021, a compound −8.0%/yr. Reported net income was −7.0B KRW in FY2025.

Key figures

Market cap 50.6B KRW (≈ $38.1M) Micro · P/S ratio 6.78 · Net margin 16.0% · Return on equity 705% · Return on assets (EBIT) −2.9% (5-year average) · Operating margin 13.1% · Revenue (TTM) 8.4B KRW · Revenue growth (YoY) +4.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (medium confidence).

What moves the price

The share trades about 65% below its 52-week high and 15% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −34% fair-value upside, at −13%, 191420 screens cheaper than that median.

Fair Value

Bear 4,225 KRW Fair Value 5,634 KRW Bull 7,042 KRW
Price 6,440 KRW · Downside -12.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 2
How much profit the company makes from its sales and capital
Quality Growth 9
Are margins and returns getting better?
Cashflow 0
Do the profits arrive as real cash?
Financial strength 71
Debt, balance sheet and risk of trouble
Investment 61
Does it invest with discipline instead of growing at any price?
Low Volatility 30
How calm the share price moves, does not count
Price momentum 7
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 82
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 24/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.5%
Start year 2020 (pandemic). Over 10 years: −2.3% a year
Revenue growth 10 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−2.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
17.9% (2020) → −74.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

191420 screens overvalued: fair value 13% below the price. Compare with ST Pharm Co →

Compare TegoScience Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 57 stocks

Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −12.5% · Above median
Profitability
Return on assets −9.0% · Bottom 25%
Net margin (12 months) 16.0% · Top 25%
Operating margin (12 months) 13.1% · Top 25%
Growth and dividend
Revenue growth (quarter YoY) 4.1% · Below median
Balance sheet
Debt / equity 0.29× · Highest 25%

Valuation Multiplesvs Pharmaceuticals median · lower = cheaper

P/B 1.00× · Cheaper than median
P/S (12 months) 6.01× · Priciest 25%
EV/EBITDA 32.1× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)17 · sector 9
FUTURE (revenue growth)21 · sector 68
PAST (return on equity)0 · sector 23
HEALTH (low debt)85 · sector 98
DIVIDEND (yield)0 · sector 27

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Huons Global Co 084110 19,530 KRW 47,019 KRW +141% vs 191420
DongKook Pharmaceutical Co 086450 26,700 KRW 28,372 KRW +6% vs 191420
ST Pharm Co 237690 75,000 KRW 61,182 KRW −18% vs 191420
Vivozon Pharmaceutical Co 082800 2,800 KRW 2,179 KRW −22% vs 191420
Oscotec Inc 039200 32,400 KRW 21,262 KRW −34% vs 191420
NatureCell Co 007390 21,300 KRW 11,176 KRW −48% vs 191420
Mezzion Pharma Co 140410 61,700 KRW 31,450 KRW −49% vs 191420
BINEX Co 053030 7,010 KRW 1,844 KRW −74% vs 191420
Caregen Co 214370 28,050 KRW 5,414 KRW −81% vs 191420
SHUKRAPHAR SHUKRAPHAR ₹82.22 ₹9.14 −89% vs 191420

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

TegoScience Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "TegoScience Inc Fair Value". https://www.fairvalue-calculator.com/stock/191420

Frequently asked questions

Is TegoScience Inc (191420) overvalued or undervalued?
As of Nov 16, 2026, our estimate of fair value is 5,634 KRW versus a price of 6,440 KRW, about 13% lower (overvalued).
What is the fair value of 191420?
Our estimate for TegoScience Inc is 5,634 KRW (as of Nov 16, 2026), built from audited fundamentals. The current price: 6,440 KRW.
What is the quality score of 191420?
TegoScience Inc has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TegoScience Inc (191420)?
We do not set a price target; the yardstick is our estimate of 5,634 KRW (as of Nov 16, 2026). Cautious scenario 4,225 KRW, optimistic scenario 7,042 KRW. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the TegoScience Inc stock forecast for 2026?
Our estimate puts fair value at 5,634 KRW, about 13% lower versus a price of 6,440 KRW (overvalued). Cautious scenario 4,225 KRW, optimistic scenario 7,042 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of TegoScience Inc (191420)?
TegoScience Inc reported trailing-twelve-month revenue of about 8.4B KRW (latest available figure, as of Nov 16, 2026).
What is the intrinsic value of TegoScience Inc (191420)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TegoScience Inc it is 5,634 KRW per share (as of Nov 16, 2026), against a price of 6,440 KRW.
Is TegoScience Inc stock overvalued or undervalued in 2026?
As of Nov 16, 2026, 191420 trades above its calculated fair value: price 6,440 KRW, fair value 5,634 KRW, a gap of about −13% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 191420?
No. The price is what the market pays today (6,440 KRW); the fair value is what the company's own numbers justify (5,634 KRW). For TegoScience Inc the two are 806.16 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is TegoScience Inc worth?
The market values TegoScience Inc at about 50.6B KRW (market capitalisation, as of Nov 16, 2026). Per share that is 6,440 KRW; our models calculate a fair value of 5,634 KRW per share.
What do the bullish and bearish scenarios say about 191420?
Our models span a range for TegoScience Inc: cautious scenario 4,225 KRW, base 5,634 KRW, optimistic 7,042 KRW per share (as of Nov 16, 2026, price 6,440 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TegoScience Inc (191420)?
Balance-sheet figures for TegoScience Inc (as of Nov 16, 2026): debt of 0.29 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is 191420 from its 52-week high?
TegoScience Inc trades at 6,440 KRW, about 65% below its 52-week high of 18,290 KRW and 15% above the low of 5,600 KRW (as of Nov 19, 2026). Distance from the high says nothing about value: that is what the fair value of 5,634 KRW is for.
Which stocks are comparable to TegoScience Inc?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Mezzion Pharma Co, NatureCell Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TegoScience Inc stock attractive at the current price?
The data as of Nov 16, 2026: price 6,440 KRW, calculated fair value 5,634 KRW (−13%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 12.0% above its aggregate fair value. TegoScience Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TegoScience Inc (191420)?
The closing price on Nov 19, 2026 was 6,440 KRW. Our estimate is 5,634 KRW, about 13% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TegoScience Inc right now?
Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. The price sits in the upper half of our model range, so the margin of safety is thin. Read the verdict with care: some models are missing inputs, so the estimate scatters more than usual.

Key figures of TegoScience Inc

How large is the market capitalisation of TegoScience Inc (191420)?
The market capitalisation of TegoScience Inc is 50.6B KRW (≈ $38.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TegoScience Inc (191420)?
The price-to-sales ratio of TegoScience Inc is 6.78 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of TegoScience Inc (191420)?
The net margin of TegoScience Inc is 16.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TegoScience Inc (191420)?
The return on equity (ROE) of TegoScience Inc is 705% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TegoScience Inc (191420)?
On an EBIT basis the return on assets of TegoScience Inc is −2.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TegoScience Inc (191420)?
The operating margin of TegoScience Inc is 13.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TegoScience Inc (191420)?
Revenue at TegoScience Inc is growing 4.1% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at TegoScience Inc (191420)?
Earnings per share at TegoScience Inc are growing 111% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does TegoScience Inc (191420) generate?
The free cash flow of TegoScience Inc is −3.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does TegoScience Inc (191420) carry?
The net debt of TegoScience Inc is 3.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch TegoScience Inc in the live analysis

One click puts TegoScience Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.